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Abstract
Background:  Obesity and type 2 diabetes mellitus (T2D) are 
known risk factors for colon cancer.  Recent reports from a number 
of genome wide association studies (GWAS) have identified several 
single nucleotide polymorphisms (SNPs) associated with obesity 
and T2D.  Here we tested the hypothesis that these SNPs may also 
be associated with risk of colon cancer.
Methods:  We genotyped nine SNPs reported in GWAS of obesity 
and/or T2D, including SNPs in HHEX, KCNJ11, SLC30A8, FTO, 
CDKN2, CDKAL1, TCF2, and the rs9300039 SNP in an intergenic 
region, in 561 colon cancer cases and 721 population controls.
Results:  None of these SNPs were statistically significantly associ-
ated with colon cancer in our sample.
Conclusions:  Overall, these results suggest that these obesity and 
T2D genetic susceptibility loci are unlikely to influence the risk of 
colon cancer.
Keywords:  Obesity; Type 2 diabetes; Colon cancer; Single nucleo-
tide polymorphisms; Association
Introduction
Obesity is now considered as a ‘probable’ cause for colon 
cancer [1], and insulin resistance with resulting metabolic 
perturbation is believed to be the key mechanism underlying 
the obesity-colon cancer link [2, 3]. Colon cancer and type 2 
diabetes mellitus (T2D) share a remarkably similar risk fac-
tor profile, including obesity, high energy intake, a Western 
diet and physical inactivity. In addition, T2D itself is directly 
associated with colon cancer [2]. It is thus plausible that ge-
netic susceptibility loci for obesity and T2D may also predis-
pose to the development of colon cancer. 
Genome-wide association studies (GWAS) have re-
cently identified a number of novel single nucleotide poly-
morphisms (SNPs) that confer susceptibility to T2D [3-7] or 
obesity [8-11]. Although the functionality of these genetic 
variants is largely unknown, many of the genes in which the 
SNPs are located are known to be oncogenic or involved in 
molecular pathways implicated in carcinogenesis. For ex-
ample, HHEX encodes a transcription factor in the homeo-
box family, and there is evidence that this gene can act as an 
oncogene [12]. CDKN2 is a well known tumor suppressor 
gene [13] which stabilizes the tumor suppressor p53.  Muta-
tions of the CDKN2 gene have been reported in numerous 
tumor types [14].  TCF2 (HNF1B), like HHEX, encodes a 
homeobox transcription factor. TCF2 has been recognized as 
a key player in carcinogenesis, especially in prostate cancer 
[15, 16]. 
To date, whether these genetic variants may also be as-
sociated with risk of cancer has not been investigated. We 
therefore tested this hypothesis in a population-based case-
control study of colon cancer.
 
Materials and Methods
   
Study population
       
The study population is described elsewhere [17]. In brief, 
we recruited 561 incident colon cancer cases and 721 popu-
lation controls. Colon cancer cases were identified via the 
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Kentucky Surveillance, Epidemiology and End Results 
(SEER) Cancer Registry within 6 months of diagnosis. Con-
trols were recruited via random digit dialing. All individuals 
were asked to donate a sample of blood for genomic DNA. 
We used the National Cancer Institute Colon Risk Factor 
Questionnaire (http://epi.grants.cancer.gov/documents/CFR/
center_questionnaires/Colon/LA/ColonRiskFactor_USC.
pdf) to collect complete lifestyle and behavioral risk fac-
tors, including demographic variables, family history of 
colorectal cancer and non-steroidal anti-inflammatory drug 
(NSAID) use. Body mass index was calculated based on 
self-reported height and weight. The response rate was ap-
proximately 72% cases, and 63% for eligible controls. The 
study was approved by the institutional review boards of 
Case Western Reserve University/University Hospitals Case 
Medical Center, the University of Kentucky, Lexington, and 
the University of Southern California, Los Angeles.
 
Selection of SNPs and genotyping
We selected nine SNPs previously identified to be associated 
with obesity (rs9939609 and rs8050136 in FTO) [8, 11] or 
T2D (rs1111875 in HHEX, rs5219 in KCNJ11, rs9300039, 
rs13266634 in SLC30A8, rs10811661 in CDKN2, rs7754840 
in CDKAL1 and rs4430796 in TCF2) [3-7], as reported in 
GWAS through September 2007. All SNPs were genotyped 
by the TAQMAN assay using predesigned probe/primer sets 
from Applied Biosystems. Two percent of samples were re-
peated giving 100% concordance.
 
Statistical analyses
        
We first tested the fit of each SNP to Hardy-Weinberg pro-
portions using a Chi-square goodness of fit. Since cases were 
specifically ascertained to a disease we hypothesize would 
be associated with these SNPs, we only used controls in this 
analysis.
To examine the association of each SNP with colon can-
cer, we initially assessed the univariate (individual SNP) 
association via a chi-square test. We further obtained odds 
ratios (OR) via a logistic regression accounting for age, sex 
and race (base model) as well as after fully adjusting for 
age, sex, race, BMI, non-steroidal anti-inflammatory drug 
(NSAID) use, and family history of colorectal cancer (full 
model). In the logistic regressions, we tested three genetic 
models (dominant, recessive or additive). For the additive 
model, each individual was coded as 0, 1 or 2, represent-
ing the number of risk (less frequent) alleles they possessed 
for each SNP. Dominant models were coded as 1 if the indi-
vidual possessed 1 or 2 copies of the risk allele, 0 otherwise, 
whereas the recessive models were coded as 1 only if the 
individual possessed two copies of the risk allele, and 0 oth-
erwise. To address possible spurious associations resulting 
from population stratification, we also performed analyses 
restricted to Caucasians only. SAS Version 9.1 (SAS Insti-
tute, Inc., Cary, North Carolina) was used to calculate all 
statistics. An α = 0.05 was used to declare statistical signifi-
cance.
 
Results
  
On average, cases were older and more likely to be male than 
controls (Table 1). Compared to controls, cases had a higher 
mean BMI (p = 0.0077), were more likely to report a family 
history of colorectal cancer (24.0% vs. 15.4%, p = 0.0014), 
more likely to be diagnosed with diabetes (20.9% vs. 15.6%, 
p = 0.019), and less likely to regularly use NSAIDs (p = 
0.16).  
All SNPs conformed to Hardy-Weinberg proportions 
among the controls (p > 0.05). We found no statistically sig-
nificant association for any of the SNPs in univariate analy-
ses (Table 1). After adjustment for potential confounders, all 
associations remained non-significant (Table 2). When the 
analyses were restricted to Caucasians, we found very simi-
lar results. For brevity, we have only presented results from 
the entire sample here.
Discussion
  
In this study, we found no association with colon cancer 
risk of a number of SNPs identified through T2D or obe-
sity GWAS. Although many of the SNPs discovered through 
GWAS have been noted to have small effect sizes, we have at 
least 80% power to detect an odds ratio as low as 1.26, which 
is typical of most variants identified through GWAS, using 
the average minor allele frequency observed in these SNPs 
(33%) and assuming an additive model. Most of the SNPs 
included here are common variants with a relatively high 
frequency (> 10%) of the minor allele homozygotes. Thus it 
is unlikely that lack of statistical power could have obscured 
true association for these genetic variants. However, caution 
needs to be exercised for the KCNJ11 rs930039 and CDNK2 
rs10811661 SNPs, for which the frequencies of the minor al-
lele homozygotes are fairly low, limiting our power to detect 
an effect of these SNPs that truly follows a recessive mode 
of inheritance. Furthermore, we were able to replicate the as-
sociation of the CDKAL1 rs7754840 SNP with self-reported 
T2D in this population, which compared to the most com-
mon GG genotype, individuals in our population with either 
the CG or CC genotype showed evidence of an increased 
risk of T2D (ORCG = 1.53, 95% CI = 1.08-2.16; ORCC = 1.63, 
95% CI = 0.97-2.73; Pdom = 0.0095 and Padd = 0.015), lending 
credibility to our results.
There are limitations to our study. After we launched 
this project, other SNPs were identified in obesity or T2D 
GWAS, including MCR4 [10], TCF7L2 [3, 4] and EXT2 [7], 
   311                                     312
Gastroenterology Research  •  2009;2(6):311-316  Association of Colon Cancer With Diabetes and Obesity
Articles © The authors, Journal compilation © Gastroenterol Res and Elmer Press™, www.gastrores.org
Cases  Controls  p*
Gender – N (%) < 0.001
     Male 266 (47.3) 274 (38.0)
     Female 295 (52.7) 447 (61.0)
Mean (stddev) age 62.8 (10.7) 58.3 (10.9) < 0.001
Race – N (%) 0.24
     African-American 27 (4.8) 23 (3.2)
     Caucasian 526 (93.8) 678 (94.0)
     Other 8 (1.4) 15 (2.1)
     Unknown 0 (0) 5 (0.7)
Body Mass Index (kg/m2) 29.3 (6.1) 28.3 (6.2) 0.0077
Diabetes Diagnosis (%)** 0.019
     Yes 105 (18.7) 105 (14.6)
     No 397 (70.8) 568 (78.8)
     Unknown 59 (10.5) 48 (6.7)
Family History‡ 0.0014
     Yes 94 (16.8) 72 (10.0)
     No 297 (52.9) 395 (54.8)
     Unknown 170 (30.3) 254 (35.2)
Regular NSAID Use† 0.16
     Yes 235 (41.9) 306 (42.4)
     No 131 (23.4) 138 (19.1)
     Unknown 195 (38.8) 277 (38.4)
HHEX – rs1111875 0.13
   CC 217 (38.7) 241 (33.4)
   CT 255 (45.5) 348 (48.3)
   TT 88 (15.7) 131 (18.2)
   No call 1 (0.2) 1 (0.1)
KCNJ11-rs5219 0.39
   CC 226 (40.3) 304 (42.2)
   CT 265 (47.2) 316 (43.8)
   TT 68 (12.1) 100 (13.9)
   No call 2 (0.4) 1 (0.1)
rs9300039 0.73
   AA 9 (1.6) 8 (1.1)
   AC 103 (18.4) 136 (18.9)
   CC 448 (79.9) 576 (79.9)
   No call 1 (0.2) 1 (0.1)
SLC30A8 – rs1326634 0.48
   CC 274 (48.9) 329 (45.6)
   CT 230 (41.0) 319 (44.2)
   TT 55 (9.8) 71 (9.9)
   No call 2 (0.4) 2 (0.3)
FTO-rs9939609 0.66
   AA 90 (16.0) 121 (16.8)
   AT 252 (44.9) 336 (46.6)
   TT 217 (38.7) 261 (36.2)
   No call 2 (0.4) 3 (0.4)
FTO-rs8050136 0.74
   AA  91 (16.2) 119 (16.5)
   AC 250 (44.6) 336 (46.6)
   CC 217 (38.7) 265 (36.8)
   No call 3 (0.5) 1 (0.1)
CDKN2 – rs10811661 0.34
   CC 21 (3.7) 19 (2.6)
   CT 142 (25.3) 202 (28.0)
   TT 395 (70.4) 500 (69.4)
   No call 3 (0.5) 0 (0)
CDKAL1 – rs7754840 0.75
   GG 241 (43.0) 325 (45.1)
   CG 254 (45.3) 313 (43.4)
   CC 64 (11.4) 81 (11.2)
   No call 2 (0.4) 2 (0.3)
TCF2 – rs4430796 0.81
   AA 141 (25.1) 178 (24.7)
   AG 297 (52.9) 374 (51.9)
   GG 122 (21.7) 168 (23.3)
   No call 1 (0.2) 1 (0.1)
*Univariate (t-test or chi-square) p-value for association with colon cancer.  For family history, type 2 diabetes diagnosis and NSAID use, this is a test of 
difference in positive vs. negative responses between cases and controls, ignoring unknown or missing data. **Self-reported physician diagnosis of type 
2 diabetes. †Regular non-steroidal anti-inflammatory drug (NSAID) use was defined as reporting ever use of NSAIDs at least twice a week for at least six 
months. ‡Family history of colorectal cancer
Table 1.  Descriptive Characteristics of Kentucky Colon Cancer Study Population
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Gene SNP Base Model* Full Model†
Case/Control OR p‡ OR p‡ 
HHEX rs1111875
   CC 217/241 1.0 (ref) 0.20 1.0 (ref) 0.22
   CT 255/348 0.80 (0.62 - 1.03) 0.79 (0.60 - 1.03)
   TT 88/131 0.85 (0.60 - 1.19) 0.87 (0.61- 1.24)
TT vs. CC/CT 0.97 (0.52 - 3.10) 0.84 1.00 (0.72 - 1.37) 0.98
CT/TT vs. CC 0.81 (0.64 - 1.03) 0.089 0.81 (0.63 - 1.04) 0.097
KCNJ11 rs5219
   CC 226/304 1.0 (ref) 0.93 1.0 (ref) 0.32
   CT 265/316 1.15 (0.90 - 1.47) 1.20 (0.92 - 1.56)
   TT 68/100 0.92 (0.63 - 1.32) 0.98 (0.67 - 1.56)
TT vs. CC/CT 0.85 (0.60 - 1.20) 0.35 0.89 (0.62 - 1.27) 0.89
CT/TT vs. CC 1.10 (0.87 - 1.39) 0.44 1.15 (0.90 - 1.47) 0.28
-- rs9300039
   CC 448/576 1.0 (ref) 0.64 1.0 (ref) 0.85
   AC 103/136 1.04 (0.78 - 1.41) 1.03 (0.75 - 1.41)
   AA 9/8 1.28 (0.48 - 3.45) 1.35 (0.46 - 3.95)
AA vs. CC/CA 1.28 (0.47 - 3.47) 0.63 1.35 (0.46 - 3.92) 0.59
AC/AA vs. CC 1.06 (0.79 - 1.41) 0.71 1.05 (0.77 - 1.42) 0.77
SLC30A8 rs13266634
   CC 274/329 1.0 (ref) 0.60 1.0 (ref) 0.61
   CT 230/319 0.92 (0.72 - 1.18) 0.88 (0.68 - 1.14)
   TT 55/71 0.94 (0.63 - 1.41) 0.99 (0.65 - 1.51)
TT vs. CC/CT 0.98 (0.67 - 1.44) 0.94 1.05 (0.70 - 1.57) 0.81
CT/TT vs. CC 0.93 (0.74 - 1.17) 0.52 0.90 (0.71 - 1.15) 0.40
FTO rs9939609
   TT 217/261 1.0 (ref) 0.35 1.0 (ref) 0.40
   AT 252/336 0.90 (0.69 - 1.15) 0.84 (0.65 - 1.10)
   AA 90/121 0.86 (0.62 - 1.22) 0.84 (0.58 - 1.19)
AA vs. TT/AT vs. AA 0.88 (0.70 - 1.12) 0.54 0.92 (0.66 - 1.27) 0.61
AT/AA vs. TT 0.92 (0.67 - 1.25) 0.32 0.84 (0.65 - 1.08) 0.17
FTO rs8050136
   CC 217/261 1.0 (ref) 0.42 1.0 (ref) 0.48
   AC 250/336 0.90 (0.70 - 1.16) 0.85 (0.65 - 1.11)
   AA 91/119 0.89 (0.64 - 1.25) 0.87 (0.61 - 1.11)
AA vs. CC/AC 0.90 (0.71 - 1.14) 0.72 0.86 (0.67 - 1.83) 0.23
AC/AA vs. CC 0.95 (0.70 - 1.29) 0.37 0.95 (0.69 - 1.32) 0.76
CDKN2 rs10811661
   TT 395/500 1.0 (ref) 0.93 1.0 (ref) 0.086
   CT 142/202 0.88 (0.68 - 1.15) 0.85 (0.65 - 1.12)
   CC 21/19 1.59 (0.83 - 3.03) 1.88 (0.93 - 3.81)
CC vs. TT/CT 1.65 (0.86 - 3.16) 0.13 1.97 (0.98 - 3.97) 0.057
CT/CC vs. TT 0.94 (0.73 - 1.21) 0.63 0.93 (0.71-1.21) 0.56
CDKAL1 rs7754840
   GG 241/325 1.0 (ref) 0.35 1.0 (ref) 0.34
   CG 254/313 1.15 (0.90 - 1.47) 1.21 (0.94 - 1.57)
   CC 64/81 1.11 (0.76 - 1.61) 1.16 (0.78 - 1.73)
CC vs. GG/CG 1.04 (0.73 - 1.50) 0.87 1.05 (0.72 - 1.53) 0.80
CG/CC vs. GG 1.14 (0.91 - 1.44) 0.25 1.20 (0.94 - 1.53) 0.15
TCF2 rs4430796
   AA 141/178 1.0 (ref) 0.39 1.0 (ref) 0.74
   AG 297/374 0.94 (0.71 - 1.25) 0.95 (0.71 - 1.28)
   GG 122/168 0.86 (0.62 - 1.20) 0.87 (0.61 - 1.24)
GG vs. AA/AG 0.90 (0.68 - 1.18) 0.43 0.90 (0.67 - 1.20) 0.48
AG/GG vs. AA 0.92 (0.70 - 1.20) 0.53 0.92 (0.70 - 1.23) 0.60
*Logistic regression controlling for age, sex and race (558 cases and 698 controls). †Logistic regression controlling for age, sex, race, family history 
of colorectal cancer, non-steroidal anti-inflammatory. drug (NSAID) use and body mass index (BMI) (503 cases and 670 controls with complete 
data). ‡p-value of additive, dominant or recessive genetic model.
Table 2. Logistic Regression Association of SNPs With Colon Cancer
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but were not included in our study. In addition, population 
stratification can bias genetic association studies and pro-
duce spurious findings [18], and we only crudely accounted 
for potential population stratification by adjusting for self-
reported race. However, given our null findings, population 
stratification does not appear to be an issue in our sample. 
Our study sample represents the general population in Ken-
tucky, which is predominantly Caucasian. The small number 
of participants other than Caucasians (< 6%) limits our abil-
ity to estimate effects in other races.  
Furthermore, we did not adjust for multiple testing in 
this study, but instead, examined these SNPs as novel candi-
date variants and tested a priori hypothesis of the existence 
of an association with colon cancer. Further adjustment for 
multiple testing would not alter our conclusion of no associa-
tion with any of these SNPs and colon cancer.
Overall, we do not find evidence of shared genetic risk 
factors for colon cancer with obesity or T2D.  However, the 
strong epidemiological and biological evidence for common 
underlying mechanisms influencing T2D and cancer war-
rants further investigation.
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